Corpus ID: 199027830

Abstract #1244: Monotherapeutic and combination antitumor activities of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer

@article{Hori2009AbstractM,
  title={Abstract #1244: Monotherapeutic and combination antitumor activities of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer},
  author={A. Hori and Osamu Kitahara and Y. Ito and Satoru Nishizawa and Y. Misumi and T. Inaoka},
  journal={Cancer Research},
  year={2009},
  volume={69},
  pages={1244-1244}
}
  • A. Hori, Osamu Kitahara, +3 authors T. Inaoka
  • Published 2009
  • Medicine
  • Cancer Research
  • Signaling of the hepatocyte growth factor (HGF)/c-Met pathway is strongly implicated in cancer progression and represents an important target for cancer treatment. TAK-701, a humanized anti-human HGF monoclonal antibody, inhibits the proliferation of cancer cells and endothelial cells in vitro and shows antitumor activity against the human glioblastoma cell line U-87 MG. Antitumor activities of TAK-701 against various cancer cells that show an autocrine dependence of HGF were investigated in… CONTINUE READING
    8 Citations
    Targeting the HGF/Met signaling pathway in cancer therapy
    • 174
    c-Met as a Target for Personalized Therapy
    • 95
    • PDF
    The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?
    • 7
    • PDF
    MET: a promising anticancer therapeutic target
    • 247
    [Advances in mesenchymal to epithelial transition factor signaling pathway and inhibitors].
    Comprehensive review of targeted therapy for colorectal cancer
    • 44
    • PDF